Genosis plc (“Genosis” or the “Company”), a UK company focusing on consumer products for reproductive health, is pleased to announce a successful fund raising and confirmation of its proposed Admission to AIM. Dealings are expected to commence in the Ordinary Shares on 2 December 2005.
Key Highlights · Genosis' first proprietary product is Fertell®, an at home fertility testing kit for both men and women. · Genosis has signed an exclusive agreement with Boots, to sell and distribute Fertell® in the UK high street. o UK launch in January 2006 · Fertell® has OTC regulatory clearance for sale in both the EU (CE) and the US (FDA). o Strong brand and patent protection in major markets worldwide o The Company estimates the world-wide potential market size for Fertell® to be >$500m p.a Details of the Placing · Genosis is raising £7.0 million before expenses through a placing of 6,363,634 shares at 110 pence per share. · Shares have been placed with institutional and other investors. · The new shares will represent approximately 41.1 per cent. of the Enlarged Issued Share Capital of the Company. · Market capitalisation on Admission is expected to be £17.0 million at the Placing Price. · Evolution Securities Limited is nominated adviser and broker to Genosis. · Dealings in the shares on AIM are expected to commence on 2 December 2005. · Genosis will have a RIC code of GNOS.L. Use of Proceeds · Strengthen the Company’s balance sheet and provide working capital injection to allow Genosis to accelerate the roll-out of Fertell® in the UK and abroad. · Investment in further automation of the manufacture of Fertell® to increase manufacturing capacity and reduce the overall cost of goods. Press Release Press Release Press Release Press Release Press Release Press Release Press Release Press Release Commenting on the planned Admission, Chief Executive Officer, Paul Bateman, said: "We are delighted to have received strong investor support on this fundraising and flotation. It’s an exciting time for Genosis. The AIM flotation provides funds to strengthen the balance sheet and increase our profile ahead of the launch of Fertell® by Boots in January 2006 and our roll out internationally”.
For further details, please contact: Genosis Today on: Paul Bateman Tel: +44 (0) 20 7466 5000
Buchanan Communications Lisa Baderoon / Rebecca Skye Dietrich Tel: +44 (0) 20 7466 5000 Evolution Securities Matt Wood / Gina Gibson Tel: +44 (0) 20 7071 4300 *Photos are available from Buchanan Communications, please call 020 7466 5000*
